Stay updated on Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.

Latest updates to the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page
- Check3 days agoChange DetectedThe page now displays the full study record for NCT03222856, replacing the prior error page and including the study overview, eligibility criteria, and locations.SummaryDifference64%

- Check10 days agoChange DetectedThe page now displays Revision: v3.6.5 instead of Revision: v3.6.4, reflecting a small version update.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision: v3.6.4 is now displayed, replacing Revision: v3.6.3. This update seems to be a site version update rather than a substantive change to the study information.SummaryDifference0.0%

- Check46 days agoChange DetectedRevision: v3.6.3 is now displayed, replacing Revision: v3.6.2. This indicates a version update for the page/system rather than a content addition or removal.SummaryDifference0.0%

- Check53 days agoChange DetectedRevision: v3.6.2 replaces v3.6.0 on the page, representing a minor update to the page's version tag. It does not change the displayed study information or user-facing content.SummaryDifference0.0%

- Check67 days agoChange DetectedThe page adds sections for No longer looking for participants, How to Read a Study Record, Common Questions, and How to Join a Study, and adjusts the Intervention/Treatment heading; it also removes the old Intervention / Treatment heading and old Revision label while adding Revision: v3.6.0.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.